GLENMARK PHARMACEUTICALS
|
GLENMARK PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -53.21 | 10.53 | 33.37 | 34.38 | 27.50 |
| CEPS(Rs) | -44.26 | 17.00 | 52.46 | 50.10 | 42.28 |
| DPS(Rs) | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 |
| Book NAV/Share(Rs) | 277.46 | 335.13 | 321.45 | 249.60 | 214.65 |
| Tax Rate(%) | 5,116.71 | 137.34 | 31.06 | 29.83 | 29.20 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 4.31 | 5.79 | 8.35 | 8.26 | 15.96 |
| EBIT Margin(%) | 1.99 | 2.09 | 6.26 | 6.88 | 13.85 |
| Pre Tax Margin(%) | 0.13 | 0.85 | 5.18 | 5.48 | 10.30 |
| PAT Margin (%) | -6.61 | -0.32 | 3.57 | 3.84 | 7.29 |
| Cash Profit Margin (%) | -4.51 | 1.70 | 5.32 | 5.60 | 11.21 |
| Performance Ratios | |||||
| ROA(%) | -11.86 | -0.54 | 6.74 | 7.11 | 6.17 |
| ROE(%) | -21.18 | -0.97 | 12.33 | 14.81 | 13.32 |
| ROCE(%) | 4.88 | 4.43 | 14.19 | 15.30 | 14.04 |
| Asset Turnover(x) | 1.79 | 1.71 | 1.89 | 1.85 | 0.85 |
| Sales/Fixed Asset(x) | 2.77 | 2.74 | 2.94 | 2.97 | 1.44 |
| Working Capital/Sales(x) | 17.22 | 7.28 | 7.74 | 7.99 | 3.97 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.36 | 0.36 | 0.34 | 0.34 | 0.70 |
| Receivable days | 36.38 | 43.76 | 37.24 | 36.01 | 78.95 |
| Inventory Days | 32.19 | 31.52 | 31.35 | 31.90 | 75.25 |
| Payable days | 190.23 | 186.18 | 191.57 | 219.98 | 218.90 |
| Valuation Parameters | |||||
| PER(x) | - | 44.14 | 13.25 | 13.51 | 7.49 |
| PCE(x) | -21.63 | 27.36 | 8.43 | 9.27 | 4.87 |
| Price/Book(x) | 3.45 | 1.39 | 1.38 | 1.86 | 0.96 |
| Yield(%) | 0.26 | 0.54 | 0.57 | 0.54 | 1.21 |
| EV/Net Sales(x) | 2.23 | 1.41 | 1.20 | 1.52 | 0.90 |
| EV/Core EBITDA(x) | 12.95 | 8.48 | 5.93 | 7.80 | 5.15 |
| EV/EBIT(x) | 47.70 | 27.69 | 8.47 | 9.60 | 6.50 |
| EV/CE(x) | 2.98 | 1.18 | 0.96 | 1.18 | 0.72 |
| M Cap / Sales | 2.29 | 1.13 | 1.01 | 1.20 | 0.55 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 1.98 | -5.86 | 12.44 | 2.85 | 7.86 |
| Core EBITDA Growth(%) | 5.79 | -22.64 | 16.51 | 14.91 | 3.55 |
| EBIT Growth(%) | -6.18 | -66.14 | 0.22 | 17.80 | -9.90 |
| PAT Growth(%) | -1,944.25 | -109.01 | 2.43 | 25.02 | -16.11 |
| EPS Growth(%) | -605.16 | -68.44 | -2.92 | 25.01 | -16.11 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.13 | 0.46 | 0.40 | 0.67 | 0.80 |
| Current Ratio(x) | 1.28 | 1.85 | 1.77 | 1.75 | 1.65 |
| Quick Ratio(x) | 0.84 | 1.33 | 1.23 | 1.21 | 1.13 |
| Interest Cover(x) | 1.07 | 1.69 | 5.83 | 4.92 | 3.90 |
| Total Debt/Mcap(x) | 0.04 | 0.33 | 0.29 | 0.36 | 0.84 |
Compare Financial Ratios of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹39,503.8 Cr | -6.8% | -12% | 57.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹409,303.0 Cr | -5.1% | -9.4% | 29.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹143,389.0 Cr | -7.3% | -10.9% | 53% | Stock Analytics | |
| CIPLA | ₹114,645.0 Cr | -1.4% | -6.7% | -1.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,449.5 Cr | -9% | -14.4% | 1.4% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹91,587.4 Cr | -7% | -5% | 22.6% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | -6.8% |
-12% |
57.4% |
| SENSEX | 0.1% |
-3.6% |
7.9% |
You may also like the below Video Courses
